A phase III trial to evaluate the activity of docetaxtel given either sequentially or in combination with doxorubicin, followed by CMF, in comparison to doxorubicin alone or in combination with cyclophosphamide, followed by CMF, in the adjuvant treatment of node-positive breast cancer patients

Study Chairs
BIG: Dr. Martine Piccart - Brussels, Belgium
IBCSG: Dr. Prue Francis - Melbourne, Australia
SAKK: Dr. Lucien Perey - Lausanne, Switzerland
SAKK: Dr. Dagmar Hess - St. Gallen, Switzerland

Trial Monitor
Giuseppe Achille
IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Date of Activation
June 1998

Date of Closure
June 26, 2001

Targeted Accrual
2730 patients

Final Accrual
2890 patients

International Breast
Cancer Study Group

Effingerstrasse 40
3008 Bern, Switzerland

Phone: +41 31 511 94 00
E-mail: ibcsgcc@ibcsg.org

Member Login